WHAT IS THE DISCOVER STUDY?
The Discover Study is a randomized, double-blind, placebo controlled study. "Randomized" means that it will be determined by chance which of the treatment groups you will be assigned to. "Double-blind" means that neither the participant nor the research team will know whether a participant is taking the placebo or the investigational drug. Participants will be treated with a low, middle, or high dose of Posiphen, or a placebo (a capsule that looks like the study drug but does not contain active ingredients).
In the Discover study, scientists will test the viability of posiphen, an investigational medication that may stop or slow the progression, or delay the onset of Alzheimer's disease (AD).
Discover is a Phase 1b study. It means that participants will help to determine the side effects of the drug and how the drug is metabolized by the human body (pharmacokinetics). The primary outcome measures of this study are safety and tolerability, pharmacokinetics measured on serum and cerebrospinal fluid, and the dose effect on the production rate of Beta Amyloid 40.
What is Posiphen?
Posiphen is a small, orally active, experimental drug that specifically inhibits the synthesis of amyloid precursor protein (APP), Tau and α-Synuclein. It is distinct from other Alzheimer's disease drugs currently in development, because it inhibits the formation of several toxic proteins, rather than removing individual toxic protein after they are produced.
It was discovered by the US National Institute on Aging (NIA) and has the potential to stop, delay or slow the progression Alzheimer's disease.